Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

The strong immune response was confirmed in CHIKV-naïve children with a 96.5% seroresponse rate (full dose) at Day 180. VLA1553 was well tolerated in children aged one to eleven years regardless of ...

EmulsiPan is an oil-in-water emulsion adjuvant and is produced by nano-emulsification of squalene along with surfactants and buffers. Squalene is a naturally occurring biodegradable and biocompatible ...

The Trump administration is eroding national pandemic flu defenses as it guts health agencies, cuts research and health ...

Biotech Vaxxas has announced a partnership agreement with the 2017-established Coalition for Epidemic Preparedness Innovations (CEPI), in order to advance the development of Vaxxas’ needle-free ...

Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...

The Trump administration’s cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

Any microbe, new or known, could cause an infection outbreak at any time. Researchers gear up to preemptively fight this ...

The program ensures funding to help coordination and communication between hospitals and first responders during a crisis.

Across the world, natural history museums hold about 3 billion specimens of plants and animals in collections—and these ...